Comparative Pharmacology
Head-to-head clinical analysis: DELTA DOME versus FLAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELTA DOME versus FLAC.
DELTA-DOME vs FLAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Delta-dome agents, likely referring to delta-9-tetrahydrocannabinol (THC) analogs or synthetic cannabinoids, act as partial agonists at cannabinoid receptors CB1 and CB2. CB1 receptors are primarily located in the central nervous system, modulating neurotransmitter release, while CB2 receptors are mainly in immune cells, influencing cytokine release and immune response.
FLAC (Fluorouracil) is a pyrimidine analog that inhibits thymidylate synthase, blocking DNA synthesis. It is converted to active metabolites (FdUMP, FUTP) that disrupt RNA function and DNA replication.
Intramuscular or subcutaneous injection of 0.5 to 1 mL (5-10 mg/mL) every 4 to 6 hours as needed.
Adults: 40 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life is 2-4 hours in adults, prolonged to 4-8 hours in hepatic impairment; correlates with duration of pulmonary effects.
2-4 hours; prolonged in renal impairment (up to 12 hours)
Primarily hepatic metabolism with renal excretion of inactive metabolites (approximately 80% in urine, 20% in feces as bile salts). Less than 1% excreted unchanged.
Renal: 70% unchanged; Fecal: 20%; Biliary: 10%
Category C
Category C
Corticosteroid
Corticosteroid